Reverse Vaccinology and Genomics

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 8842

Special Issue Editor


E-Mail Website
Guest Editor
ANSES - French Agency for Food, Environmental and Occupational Health & Safety, Ploufragan-Plouzane-Niort Laboratory, Viral Genetics and Biosafety Unit, 22440 Ploufragan, France
Interests: porcine; chicken and fish vaccinology; identification of novel vaccine antigens; reverse vaccinology; antibody repertoire; DNA vaccination; mucosal vaccination
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Novel strategies based on the analysis of the pathogens’ genome developed over the last years enable to identify efficient vaccine antigens. These strategies are known under the name of reverse vaccinology. At the beginning, it consisted in manual screening of hundreds of potential proteins of the pathogen. Thereafter in silico analyses, using specific software and databases, helped to identify Open Reading Frames (ORFs) encoding potential vaccine antigens. Thus, only a low number of vaccine candidates has to be evaluated in vivo for their protective potentials. Such studies were first performed to develop new human vaccines. There is a need to develop specific reverse vaccinology tools for veterinary purposes.

The aim of this specific issue will be to publish papers describing the development or optimization of human or veterinary vaccines identified through reverse vaccinology strategies. Another part of this issue will be the description of novel reverse vaccinology tools, including those specifically dedicated to veterinary species. A special interest will be on the development of tools potentially detecting T-cell antigens.

Dr. Daniel Dory
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel reverse vaccinology tools
  • veterinary reverse vaccinology tools
  • novel vaccines identified through reverse vaccinology strategy
  • B-cell antigens identification
  • T-cell antigens identification
  • bacteria vaccine antigens
  • virus vaccine antigens
  • parasite vaccine antigens

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 3280 KiB  
Article
Reduced Virus Load in Lungs of Pigs Challenged with Porcine Reproductive and Respiratory Syndrome Virus after Vaccination with Virus Replicon Particles Encoding Conserved PRRSV Cytotoxic T-Cell Epitopes
by Simon Welner, Nicolas Ruggli, Matthias Liniger, Artur Summerfield, Lars Erik Larsen and Gregers Jungersen
Vaccines 2021, 9(3), 208; https://doi.org/10.3390/vaccines9030208 - 2 Mar 2021
Cited by 1 | Viewed by 3804
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe respiratory distress and reproductive failure in swine. Modified live virus (MLV) vaccines provide the highest degree of protection and are most often the preferred choice. While somewhat protective, the use of MLVs is accompanied [...] Read more.
Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe respiratory distress and reproductive failure in swine. Modified live virus (MLV) vaccines provide the highest degree of protection and are most often the preferred choice. While somewhat protective, the use of MLVs is accompanied by multiple safety issues, why safer alternatives are urgently needed. Here, we describe the generation of virus replicon particles (VRPs) based on a classical swine fever virus genome incapable of producing infectious progeny and designed to express conserved PRRSV-2 cytotoxic T-cell epitopes. Eighteen pigs matched with the epitopes by their swine leucocyte antigen-profiles were vaccinated (N = 11, test group) or sham-vaccinated (N = 7, control group) with the VRPs and subsequently challenged with PRRSV-2. The responses to vaccination and challenge were monitored using serological, immunological, and virological analyses. Challenge virus load in serum did not differ significantly between the groups, whereas the virus load in the caudal part of the lung was significantly lower in the test group compared to the control group. The number of peptide-induced interferon-γ secreting cells after challenge was higher and more frequent in the test group than in the control group. Together, our results provide indications of a shapeable PRRSV-specific cell-mediated immune response that may inspire future development of effective PRRSV vaccines. Full article
(This article belongs to the Special Issue Reverse Vaccinology and Genomics)
Show Figures

Figure 1

17 pages, 2103 KiB  
Article
Orf Virus-Based Vaccine Vector D1701-V Induces Strong CD8+ T Cell Response against the Transgene but Not against ORFV-Derived Epitopes
by Alena Reguzova, Michael Ghosh, Melanie Müller, Hanns-Joachim Rziha and Ralf Amann
Vaccines 2020, 8(2), 295; https://doi.org/10.3390/vaccines8020295 - 10 Jun 2020
Cited by 19 | Viewed by 4234
Abstract
The potency of viral vector-based vaccines depends on their ability to induce strong transgene-specific immune response without triggering anti-vector immunity. Previously, Orf virus (ORFV, Parapoxvirus) strain D1701-V was reported as a novel vector mediating protection against viral infections. The short-lived ORFV-specific immune [...] Read more.
The potency of viral vector-based vaccines depends on their ability to induce strong transgene-specific immune response without triggering anti-vector immunity. Previously, Orf virus (ORFV, Parapoxvirus) strain D1701-V was reported as a novel vector mediating protection against viral infections. The short-lived ORFV-specific immune response and the absence of virus neutralizing antibodies enables repeated immunizations and enhancement of humoral immune responses against the inserted antigens. However, only limited information exists about the D1701-V induced cellular immunity. In this study we employed major histocompatibility complex (MHC) ligandomics and immunogenicity analysis to identify ORFV-specific epitopes. Using liquid chromatography-tandem mass spectrometry we detected 36 ORFV-derived MHC I peptides, originating from various proteins. Stimulated splenocytes from ORFV-immunized mice did not exhibit specific CD8+ T cell responses against the tested peptides. In contrast, immunization with ovalbumin-expressing ORFV recombinant elicited strong SIINFEKL-specific CD8+ T lymphocyte response. In conclusion, our data indicate that cellular immunity to the ORFV vector is negligible, while strong CD8+ T cell response is induced against the inserted transgene. These results further emphasize the ORFV strain D1701-V as an attractive vector for vaccine development. Moreover, the presented experiments describe prerequisites for the selection of T cell epitopes exploitable for generation of ORFV-based vaccines by reverse genetics. Full article
(This article belongs to the Special Issue Reverse Vaccinology and Genomics)
Show Figures

Figure 1

Back to TopTop